Status: current, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jul 2019. Module: SNOMED CT core
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 3773045010 | Vascular endothelial growth factor receptor antagonist (disposition) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3773046011 | Vascular endothelial growth factor receptor antagonist | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 4167521016 | VEGF antagonist | en | Synonym (core metadata concept) | Active | Entire term case sensitive (core metadata concept) | SNOMED CT core |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Vascular endothelial growth factor receptor antagonist (disposition) | Is a | Receptor antagonist (disposition) | true | Inferred relationship | Some |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
| Sunitinib (substance) | Has disposition (attribute) | True | Vascular endothelial growth factor receptor antagonist (disposition) | Inferred relationship | Some | |
| Substance with vascular endothelial growth factor receptor antagonist mechanism of action (substance) | Has disposition (attribute) | True | Vascular endothelial growth factor receptor antagonist (disposition) | Inferred relationship | Some | |
| Sunitinib malate (substance) | Has disposition (attribute) | True | Vascular endothelial growth factor receptor antagonist (disposition) | Inferred relationship | Some | |
| Bevacizumab (substance) | Has disposition (attribute) | True | Vascular endothelial growth factor receptor antagonist (disposition) | Inferred relationship | Some | |
| Ranibizumab (substance) | Has disposition (attribute) | True | Vascular endothelial growth factor receptor antagonist (disposition) | Inferred relationship | Some | |
| Pegaptanib sodium (substance) | Has disposition (attribute) | True | Vascular endothelial growth factor receptor antagonist (disposition) | Inferred relationship | Some | |
| Sorafenib (substance) | Has disposition (attribute) | True | Vascular endothelial growth factor receptor antagonist (disposition) | Inferred relationship | Some | |
| Pegaptanib (substance) | Has disposition (attribute) | True | Vascular endothelial growth factor receptor antagonist (disposition) | Inferred relationship | Some | |
| Vandetanib (substance) | Has disposition (attribute) | True | Vascular endothelial growth factor receptor antagonist (disposition) | Inferred relationship | Some | |
| Axitinib (substance) | Has disposition (attribute) | True | Vascular endothelial growth factor receptor antagonist (disposition) | Inferred relationship | Some | |
| Sorafenib tosylate (substance) | Has disposition (attribute) | True | Vascular endothelial growth factor receptor antagonist (disposition) | Inferred relationship | Some | |
| Cabozantinib (substance) | Has disposition (attribute) | True | Vascular endothelial growth factor receptor antagonist (disposition) | Inferred relationship | Some | |
| Lenvatinib mesilate | Has disposition (attribute) | True | Vascular endothelial growth factor receptor antagonist (disposition) | Inferred relationship | Some | |
| Pazopanib hydrochloride (substance) | Has disposition (attribute) | True | Vascular endothelial growth factor receptor antagonist (disposition) | Inferred relationship | Some | |
| Pazopanib (substance) | Has disposition (attribute) | True | Vascular endothelial growth factor receptor antagonist (disposition) | Inferred relationship | Some | |
| Lenvatinib | Has disposition (attribute) | True | Vascular endothelial growth factor receptor antagonist (disposition) | Inferred relationship | Some | |
| Ramucirumab | Has disposition (attribute) | True | Vascular endothelial growth factor receptor antagonist (disposition) | Inferred relationship | Some | |
| Regorafenib | Has disposition (attribute) | True | Vascular endothelial growth factor receptor antagonist (disposition) | Inferred relationship | Some | |
| Aflibercept | Has disposition (attribute) | True | Vascular endothelial growth factor receptor antagonist (disposition) | Inferred relationship | Some | |
| Brolucizumab (substance) | Has disposition (attribute) | True | Vascular endothelial growth factor receptor antagonist (disposition) | Inferred relationship | Some | |
| Cabozantinib s-malate | Has disposition (attribute) | True | Vascular endothelial growth factor receptor antagonist (disposition) | Inferred relationship | Some | |
| Faricimab (substance) | Has disposition (attribute) | True | Vascular endothelial growth factor receptor antagonist (disposition) | Inferred relationship | Some |
Reference Sets
FHIR